An Epidemiological Study of Neuropathic Pain Symptoms in Canadian Adults
Table 2
Percent of respondents with pain-related diagnoses who were screened positive for neuropathic characteristics on the S-LANSS and the DN4.
Total
Diagnosed with pain condition
Sample () (%)
Population (,423,076) %
S-LANSS ≥ 12 (,128,817) %
DN4 ≥ 3 (,264,722) %
Likely neuropathic diagnosis
Accident with nerve damage
72 (4.8)
4.9
31.4
51.6
Shingles
32 (2.1)
1.6
29.0
48.0
Amputation
3 (0.2)
0.2
51.9
100
Possible neuropathic diagnosis
Back
297 (19.7)
19.2
19.6
32.3
Surgery
123 (8.2)
8.8
33.5
40.8
Diabetes
104 (6.9)
4.9
34.3
39.4
Cancer
31 (2.1)
1.5
37.1
36.6
Unlikely neuropathic diagnosis
Osteoarthritis
239 (15.9)
12.6
9.1
11.0
Arthritis—osteoarthritis or rheumatoid
114 (7.6)
7.0
25.9
17.3
Migraine
98 (6.5)
6.7
17.6
17.4
Rheumatoid arthritis
59 (3.9)
3.2
19.9
12.5
Chronic widespread pain
39 (2.6)
2.5
25.3
56.4
Fibromyalgia
35 (2.3)
1.9
37.5
50.6
Leg ulcers
6 (0.4)
0.3
0.0
0.0
Vulvodynia
4 (0.3)
0.2
0.0
67.6
Individuals could select more than 1 condition. The percentage screening positive for possible neuropathic diagnosis excludes those with a concurrent likely neuropathic diagnosis. The percentage screening positive for unlikely neuropathic diagnosis excludes those with a concurrent likely or possible neuropathic diagnosis. S-LANSS = Self-Report Leeds Assessment of Neuropathic Symptoms and Signs; DN4 = Douleur Neuropathique 4.
